Teratogen update: Methotrexate
- 20 March 2012
- journal article
- review article
- Published by Wiley in Birth Defects Research Part A: Clinical and Molecular Teratology
- Vol. 94 (4), 187-207
- https://doi.org/10.1002/bdra.23003
Abstract
Methotrexate and aminopterin are folic acid antagonists that inhibit dihydrofolate reductase, resulting in a block in the synthesis of thymidine and inhibition of DNA synthesis. Methotrexate has been used for the treatment of malignancy, rheumatic disorders, and psoriasis and termination of intrauterine pregnancy. Recently, methotrexate has become a standard treatment for ectopic pregnancy. The misdiagnosis of an intrauterine pregnancy as an ectopic pregnancy can result in exposure of a continuing pregnancy to dose levels of methotrexate of 50 mg/m2 (maternal body surface area). Experimental animal studies have associated methotrexate therapy with embryo death in mice, rats, rabbits, and monkeys. Structural malformations have been most consistently produced in rabbits at a maternal dose level of 19.2 mg/kg. Abnormalities in rabbits include hydrocephalus, microphthalmia, cleft lip and palate, micrognathia, dysplastic sacral and caudal vertebrate, phocomelia, hemimelia, syndactyly, and ectrodactyly. Based on human case reports of methotrexate exposure during pregnancy, a methotrexate embryopathy has been described that includes growth deficiency, microcephaly, hypoplasia of skull bones, wide fontanels, coronal or lambdoidal craniosynostosis, upswept frontal scalp hair, broad nasal bridge, shallow supraorbital ridges, prominent eyes, low‐set ears, maxillary hypoplasia, epicanthal folds, short limbs, talipes, hypodactyly, and syndactyly. This syndrome may be associated with exposures between 6 and 8 weeks after conception and dose levels of 10 mg/week or greater. More recent case reports of methotrexate exposure for the misdiagnosis of ectopic pregnancy involve treatment before 6 weeks after conception and have raised the suggestion of a distinct syndrome due to such early exposures. Tetralogy of Fallot and perhaps other neural crest cell‐related abnormalities may be features of this early syndrome. A disproportionality analysis of methotrexate and aminopterin case reports and series provides support for pulmonary atresia, craniosynostosis, and limb deficiencies as reported more often than expected in methotrexate‐exposed children. Denominator‐based data will be welcome to better define elements of a methotrexate embryopathy and possibly to distinguish an early exposure syndrome from anomalies traditionally associated with methotrexate exposure. Birth Defects Research (Part A), 2012.Keywords
This publication has 45 references indexed in Scilit:
- Outcome following high-dose methotrexate in pregnancies misdiagnosed as ectopicAmerican Journal of Obstetrics and Gynecology, 2011
- Methotrexate embryopathy after therapy for misdiagnosed ectopic pregnancyInternational Journal of Gynecology & Obstetrics, 2007
- Methotrexate/misoprostol embryopathy: Report of four cases resulting from failed medical abortionAmerican Journal of Medical Genetics, 2003
- In utero first trimester exposure to low-dose methotrexate with increased fetal nuchal translucency and associated malformationsPrenatal Diagnosis, 2002
- Multiple anomalies in a fetus exposed to low-dose methotrexate in the first trimesterObstetrics & Gynecology, 2002
- Methotrexate increases valproic acid‐induced developmental toxicity, in particular neural tube defects in miceTeratogenesis, Carcinogenesis, and Mutagenesis, 1992
- Comparative ultrastructural alterations in rabbit limb-buds after a teratogenic dose of either hydroxyurea or methotrexateTeratology, 1981
- Drug-induced limb dysplasias in fetal rabbitsTeratology, 1977
- Teratogenicity of methotrexate in miceTeratology, 1974
- Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)The New England Journal of Medicine, 1948